Company: JUNS
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023603
Chunk: 34

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Item 8
Chunk 34
---
 this Quarterly Report on Form 10-Q, there have been no material updates or changes with respect to the risk factors previously disclosed
in our Annual Report on Form 10-K, other than as set forth below, which should be read in conjunction with the risk described in our
Annual Report on Form 10-K.

Risks
Related to the STANDBY EQUITY PURCHASE AGREEMENT

Substantial
blocks of our common stock may be sold into the market as a result of the convertible notes we sold or will sell to YA II PN, Ltd. or
shares of Common Stock we may sell to YA II PN, Ltd., in each case, under the Standby Equity Purchase Agreement, if not terminated and
if and when available, which may cause the price of our Common Stock to decline.

On
October 27, 2025, the Company entered into a Standby Equity Purchase Agreement (“SEPA”) and related Registration Rights
Agreement with YA II PN, Ltd. (“Yorkville”). Subject to the terms and conditions set forth therein, Yorkville agreed to
advance to us up to $6.0 million, in two tranches, less certain amounts (the “Pre-Paid Advances”) in exchange for
convertible promissory notes (each, a “Convertible Note” and, together, the “Convertible Notes”) issued by
us. On October 27, 2025, Yorkville disbursed the first tranche of the Pre-Paid Advances, in the amount of $3,720,000 after
accounting for original issue discount (“OID”), to us. In exchange, we issued Yorkville a first Convertible Note for the
principal amount of $4.0 million. It is anticipated that Yorkville will disburse the second tranche of the pre-paid advance, in the
amount of $1,860,000 after accounting for OID, to us on the second trading day after the later of either of the following: (i) the
effective date of an initial registration statement registering the resale of the shares of Common Stock, as issuable pursuant to
the SEPA, under the Securities Act of 1933, as amended (the “Securities Act”) or (ii) our receipt of the requisite
approval of our stockholders enabling us to issue shares of Common Stock to Yorkville under the SEPA, and upon conversion of the
Convertible Notes, collectively, in excess of the Exchange Cap (as defined below). In exchange, at the